Details for Patent: 10,512,620

Which drugs does patent 10,512,620 protect, and when does it expire?

Patent 10,512,620 protects SOTALOL HYDROCHLORIDE and is included in one NDA.

Summary for Patent: 10,512,620

Patent landscape, scope, and claims:

Title:	Method of initiating and escalating sotalol hydrochloride dosing
Abstract:	This disclosure provides method of safely and efficaciously treating or preventing atrial fibrillation, atrial flutter, or a combination thereof via rapid intravenous introduction of sotalol hydrochloride to a subject in need thereof.
Inventor(s):	Somberg; John Charin (Chicago, IL), Kashfian; Brandon Ira (Chicago, IL), Molnar; Janos (Chicago, IL)
Assignee:	AltaThera Pharmaceuticals, LLC (Chicago, IL)
Application Number:	16/103,815
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,512,620
Patent Claim Types: see list of patent claims	Use; Delivery; Dosage form;

Drugs Protected by US Patent 10,512,620

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Altathera Pharms Llc	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	SOLUTION;INTRAVENOUS	022306-001	Jul 2, 2009		RX	Yes	Yes	10,512,620					DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION.
Altathera Pharms Llc	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	SOLUTION;INTRAVENOUS	022306-001	Jul 2, 2009		RX	Yes	Yes	10,512,620					INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE EXPOSURE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING